OncoMatch/Clinical Trials/NCT06540443
Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Is NCT06540443 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MPB-2043 of 0.5 mg/kg and MPB-2043 of 1.0 mg/kg for head and neck squamous cell carcinoma.
Treatment: MPB-2043 of 0.5 mg/kg · MPB-2043 of 1.0 mg/kg · MPB-2043 of 2.0 mg/kg · MPB-2043 of 3.0 mg/kg — This study evaluates the safety and effectiveness of MPB-2043, a superparamagnetic iron oxide (SPIO) contrast agent, for enhancing MRI in detecting metastatic lymph nodes in head and neck cancer. The study compares four doses of MPB-2043 (0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 3 mg/kg) and assesses the optimal timing for post-dose imaging using T1/T2/T2\*-weighted sequences to improve the accuracy of nodal staging.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Cannot have received: surgery
Lab requirements
Blood counts
No bone marrow disorders or history of bone marrow transplant
Kidney function
No kidney disease or impairment
Liver function
No liver or spleen disease or impairment based on clinical imaging and laboratory results
Cardiac function
No active and clinically significant cardiac diseases
Subjects with kidney disease or impairment. Subjects with liver or spleen disease or impairment based on other clinical imaging, such as CT or gadolinium contrast MRI, and clinical laboratory results. Subjects with bone marrow disorders or a history of a bone marrow transplant. Subjects with active and clinically significant cardiac diseases.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify